These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17689998)

  • 1. Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy.
    Ohashi T; Sakuma M; Kitagawa T; Suzuki K; Ishige N; Eto Y
    Mol Genet Metab; 2007 Nov; 92(3):271-3. PubMed ID: 17689998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.
    Vedder AC; Breunig F; Donker-Koopman WE; Mills K; Young E; Winchester B; Ten Berge IJ; Groener JE; Aerts JM; Wanner C; Hollak CE
    Mol Genet Metab; 2008 Jul; 94(3):319-25. PubMed ID: 18424138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
    Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
    Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
    Bénichou B; Goyal S; Sung C; Norfleet AM; O'Brien F
    Mol Genet Metab; 2009 Jan; 96(1):4-12. PubMed ID: 19022694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease.
    Wraith JE; Tylki-Szymanska A; Guffon N; Lien YH; Tsimaratos M; Vellodi A; Germain DP
    J Pediatr; 2008 Apr; 152(4):563-70, 570.e1. PubMed ID: 18346516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agalsidase Beta: a review of its use in the management of Fabry disease.
    Keating GM; Simpson D
    Drugs; 2007; 67(3):435-55. PubMed ID: 17335299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.
    Linthorst GE; Hollak CE; Donker-Koopman WE; Strijland A; Aerts JM
    Kidney Int; 2004 Oct; 66(4):1589-95. PubMed ID: 15458455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry.
    Wilcox WR; Linthorst GE; Germain DP; Feldt-Rasmussen U; Waldek S; Richards SM; Beitner-Johnson D; Cizmarik M; Cole JA; Kingma W; Warnock DG
    Mol Genet Metab; 2012 Mar; 105(3):443-9. PubMed ID: 22227322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al.
    Linthorst GE; Aerts JM
    J Inherit Metab Dis; 2011 Feb; 34(1):237-8. PubMed ID: 20938807
    [No Abstract]   [Full Text] [Related]  

  • 10. Spotlight on agalsidase beta in Fabry disease.
    Keating GM; Simpson D
    BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabry disease, enzyme replacement therapy and the significance of antibody responses.
    Deegan PB
    J Inherit Metab Dis; 2012 Mar; 35(2):227-43. PubMed ID: 22037707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.
    Rombach SM; Aerts JM; Poorthuis BJ; Groener JE; Donker-Koopman W; Hendriks E; Mirzaian M; Kuiper S; Wijburg FA; Hollak CE; Linthorst GE
    PLoS One; 2012; 7(10):e47805. PubMed ID: 23094092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
    Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
    J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.
    Schiffmann R; Ries M; Blankenship D; Nicholls K; Mehta A; Clarke JT; Steiner RD; Beck M; Barshop BA; Rhead W; West M; Martin R; Amato D; Nair N; Huertas P
    Genet Med; 2013 Dec; 15(12):983-9. PubMed ID: 23680766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval.
    Desnick RJ
    Expert Opin Biol Ther; 2004 Jul; 4(7):1167-76. PubMed ID: 15268683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.
    Lubanda JC; Anijalg E; Bzdúch V; Thurberg BL; Bénichou B; Tylki-Szymanska A
    Genet Med; 2009 Apr; 11(4):256-64. PubMed ID: 19265719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing antibodies to alpha-galactosidase A in Fabry disease.
    Richards SM
    Clin Ther; 2007; 29 Suppl A():S7-8. PubMed ID: 17580240
    [No Abstract]   [Full Text] [Related]  

  • 18. Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha.
    Tanaka A; Takeda T; Hoshina T; Fukai K; Yamano T
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S249-52. PubMed ID: 20567910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.
    Vedder AC; Linthorst GE; Houge G; Groener JE; Ormel EE; Bouma BJ; Aerts JM; Hirth A; Hollak CE
    PLoS One; 2007 Jul; 2(7):e598. PubMed ID: 17622343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.
    Nakano S; Tsukimura T; Togawa T; Ohashi T; Kobayashi M; Takayama K; Kobayashi Y; Abiko H; Satou M; Nakahata T; Warnock DG; Sakuraba H; Shibasaki F
    PLoS One; 2015; 10(6):e0128351. PubMed ID: 26083343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.